drugset / Trial / NCT00348452

A Study Comparing the Effectiveness and Safety of Extended Release Tramadol HCl at 100 mg, 200 mg and 300 mg Doses to Placebo for the Treatment of Moderate to Severe Pain Due to Osteoarthritis (OA)

NCT00348452

Phase 3 Completed 1000 enrolled Bausch Health Americas, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to compare the analgesic efficacy and safety of tramadol HCl ER 100 mg, 200 mg and 300 mg once a day (QD), with placebo in patients with moderate to severe pain due to OA. For the purposes of this study, celecoxib will serve as a positive control to validate the sensitivity of the model. The study hypothesis is that tramadol HCl ER is safe and effective in the treatment of moderate to severe pain due to OA.

Timeline

Start
2002-09
Primary completion
Completion
2003-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Celecoxib Other / unclassified 200 mg
Subject Tramadol Other / unclassified 100 mg
Subject Tramadol Other / unclassified 200 mg
Subject Tramadol Other / unclassified 300 mg

Indications